False Claims Act Appeal Tests Janssen's $1.6B Penalty
Third Circuit reviews Janssen's $1.6B False Claims Act appeal.
Why it matters: The case may influence corporate compliance strategies with federal contracts and FCA's application.
- Janssen argues the $1.6B judgment is excessive.
- The case involves 159,574 false claims for HIV drugs.
- Janssen raises Eighth Amendment concerns and FCA criteria issues.
- DOJ contends FCA's constitutionality against Janssen's claims.
The Third Circuit Court of Appeals is reviewing a pivotal case challenging a $1.6 billion judgment against Janssen Products LP under the False Claims Act (FCA). This judgment relates to alleged false claims on the HIV drugs Prezista and Intelence due to improper marketing practices.
A jury originally found Janssen responsible for 159,574 false claims, awarding $120 million in damages, which were later trebled with added penalties to form one of the largest-ever FCA judgments.
Janssen contends the penalty violates the Eighth Amendment prohibiting excessive fines. They also challenge the FCA’s materiality and falsity criteria and raise constitutional concerns over "qui tam" provisions, allowing private individuals to sue on the government's behalf.
Meanwhile, the Department of Justice defends the FCA's constitutionality and addresses claims Janssen made about judicial instructions on Medicare reimbursements and FDA authorizations.
If the Third Circuit agrees with Janssen on jury instruction errors, especially concerning Medicare rules, it could lead to a precedent-changing decision, either by overturning the judgment or mandating adjustments.
By the numbers:
- $1.6 billion — Judgment amount Janssen seeks to overturn.
- 159,574 — Number of false claims involved in the case.
- $120 million — Initial damages awarded before trebling and penalties.
Yes, but: The DOJ maintains that FCA provisions are constitutionally sound.
What's next: Awaiting the Third Circuit's decision, which could redefine FCA's scope and enforcement.